Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer.

Vos CG, Dahele M, Dickhoff C, Senan S, Thunnissen E, Hartemink KJ.

Acta Oncol. 2013 Apr;52(3):676-8. doi: 10.3109/0284186X.2012.718794. No abstract available.

PMID:
23098694
2.

Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?

Steger V, Spengler W, Hetzel J, Veit S, Walker T, Mustafi M, Friedel G, Walles T.

Eur J Cardiothorac Surg. 2012 Apr;41(4):880-5; discussion 885. doi: 10.1093/ejcts/ezr160.

PMID:
22233799
3.

Sleeve lobectomy after induction chemoradiotherapy.

Gómez-Caro A, Boada M, Reguart N, Viñolas N, Casas F, Molins L.

Eur J Cardiothorac Surg. 2012 May;41(5):1052-8. doi: 10.1093/ejcts/ezr184.

PMID:
22223693
4.

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer.

Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, Stamatis G.

J Thorac Cardiovasc Surg. 2010 Jun;139(6):1424-30. doi: 10.1016/j.jtcvs.2010.02.039.

5.

Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy.

Okubo K, Kobayashi M, Morikawa H, Hayatsu E.

Jpn J Thorac Cardiovasc Surg. 2006 Jul;54(7):268-72.

PMID:
16898638
6.

Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.

Chen F, Okubo K, Sonobe M, Shibuya K, Matsuo Y, Kim YH, Yanagihara K, Bando T, Date H.

World J Surg. 2012 Dec;36(12):2858-64. doi: 10.1007/s00268-012-1747-1.

PMID:
22926283
7.

[Pre-operative plasma D-dimer level may predict the poor prognosis within one year after the surgery for non-small cell lung cancer].

Wang Z, Fu J, Diao D, Dang C.

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):534-7. doi: 10.3779/j.issn.1009-3419.2011.06.10. Chinese.

8.

Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.

Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, Yu J, Li B.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1628-35. doi: 10.1007/s00259-011-1838-5.

PMID:
21617977
9.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.

10.

Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer.

Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Maeda H, Ohta M.

Ann Thorac Cardiovasc Surg. 2012;18(6):530-5.

11.

[Chemo-radiotherapy before surgery in stage III non-small-cell lung cancer].

Bonnette P.

Rev Mal Respir. 2013 Feb;30(2):105-14. doi: 10.1016/j.rmr.2012.08.010. Review. French.

PMID:
23419441
12.

Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.

Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK.

Lung Cancer. 2011 Dec;74(3):446-50. doi: 10.1016/j.lungcan.2011.05.003.

PMID:
21676484
13.

Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection.

Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N.

J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93.

14.

Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.

Meacci E, Cesario A, Cusumano G, Lococo F, D'Angelillo R, Dall'armi V, Margaritora S, Granone P.

Eur J Cardiothorac Surg. 2011 Sep;40(3):656-63. doi: 10.1016/j.ejcts.2010.12.062.

PMID:
21402479
15.

Comparison of clinical and pathological tumor, node and metastasis staging of lung cancer: 15-year experience with 530 patients.

Turk F, Gursoy S, Yaldiz S, Yuncu G, Yazgan S, Basok O.

Minerva Chir. 2011 Dec;66(6):509-16.

PMID:
22233657
16.

Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.

Cho JH, Kim J, Kim K, Shim YM, Kim HK, Choi YS.

World J Surg. 2012 May;36(5):1199-205. doi: 10.1007/s00268-012-1472-9.

PMID:
22374538
17.

Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.

Manac'h D, Riquet M, Medioni J, Le Pimpec-Barthes F, Dujon A, Danel C.

Ann Thorac Surg. 2001 Apr;71(4):1088-93.

PMID:
11308141
18.

Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma.

Clark JI, Albain KS.

Cancer Treat Res. 2001;105:149-70. Review. No abstract available.

PMID:
11224986
19.

Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer.

Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, Matzinger O, Ris HB, Gronchi F, Lovis A, Peters S.

Ann Thorac Surg. 2013 Jul;96(1):247-52. doi: 10.1016/j.athoracsur.2013.04.009.

PMID:
23684158
20.

Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.

Higgins K, Chino JP, Marks LB, Ready N, D'Amico TA, Clough RW, Kelsey CR.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1462-7. doi: 10.1016/j.ijrobp.2009.01.069.

PMID:
19467798
Items per page

Supplemental Content

Support Center